Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / Common Stock, $0.00001 par value
-
Shares outstanding
-
120,020,745
-
Total 13F shares
-
28,502,589
-
Share change
-
+2,892,694
-
Total reported value
-
$734,504,527
-
Put/Call ratio
-
8.4%
-
Price per share
-
$25.81
-
Number of holders
-
102
-
Value change
-
+$71,530,796
-
Number of buys
-
65
-
Number of sells
-
36
Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) as of Q3 2017
As of 30 Sep 2017,
Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) was held by
102 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
28,502,589 shares.
The largest 10 holders included
Vivo Capital, LLC, FMR LLC, FRANKLIN RESOURCES INC, BlackRock Inc., DEERFIELD MANAGEMENT CO, Sofinnova Management VIII, L.L.C., EAGLE ASSET MANAGEMENT INC, Polar Capital LLP, VANGUARD GROUP INC, and WESTFIELD CAPITAL MANAGEMENT CO LP.
This page lists
101
institutional shareholders reporting positions in this security
for the Q3 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.